103 related articles for article (PubMed ID: 21972727)
1. [Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?].
Esser N; Paquot N; Scheen AJ
Rev Med Suisse; 2011 Aug; 7(306):1614-8, 1620. PubMed ID: 21972727
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Esser N; Paquot N; Scheen AJ
Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
[TBL] [Abstract][Full Text] [Related]
3. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.
Esser N; Legrand-Poels S; Piette J; Scheen AJ; Paquot N
Diabetes Res Clin Pract; 2014 Aug; 105(2):141-50. PubMed ID: 24798950
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and insulin resistance.
Shoelson SE; Lee J; Goldfine AB
J Clin Invest; 2006 Jul; 116(7):1793-801. PubMed ID: 16823477
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and chronic cardiovascular inflammatory syndrome.
Fernández-Real JM; Ricart W
Endocr Rev; 2003 Jun; 24(3):278-301. PubMed ID: 12788800
[TBL] [Abstract][Full Text] [Related]
6. [Chronic mild inflammation links obesity, metabolic syndrome, atherosclerosis and diabetes].
Andel M; Polák J; Kraml P; Dlouhý P; Stich V
Vnitr Lek; 2009; 55(7-8):659-65. PubMed ID: 19731872
[TBL] [Abstract][Full Text] [Related]
7. Nutritional anti-inflammatories in the treatment and prevention of type 2 diabetes mellitus and the metabolic syndrome.
Merone L; McDermott R
Diabetes Res Clin Pract; 2017 May; 127():238-253. PubMed ID: 28402903
[TBL] [Abstract][Full Text] [Related]
8. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Yamagishi S; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
Scheen AJ; Esser N; Paquot N
Diabetes Metab; 2015 Jun; 41(3):183-94. PubMed ID: 25794703
[TBL] [Abstract][Full Text] [Related]
10. Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes.
Kuryłowicz A; Koźniewski K
Molecules; 2020 May; 25(9):. PubMed ID: 32397353
[TBL] [Abstract][Full Text] [Related]
11. Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review.
Hassani FV; Shirani K; Hosseinzadeh H
Naunyn Schmiedebergs Arch Pharmacol; 2016 Sep; 389(9):931-49. PubMed ID: 27178264
[TBL] [Abstract][Full Text] [Related]
12. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
13. Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood.
Connaughton RM; McMorrow AM; McGillicuddy FC; Lithander FE; Roche HM
Proc Nutr Soc; 2016 May; 75(2):115-24. PubMed ID: 26934951
[TBL] [Abstract][Full Text] [Related]
14. Inflammation, cytokines and insulin resistance: a clinical perspective.
Wieser V; Moschen AR; Tilg H
Arch Immunol Ther Exp (Warsz); 2013 Apr; 61(2):119-25. PubMed ID: 23307037
[TBL] [Abstract][Full Text] [Related]
15. [Obesity--insulin resistance--type 2 diabetes mellitus].
Małecki MT
Kardiol Pol; 2006 Oct; 64(10 Suppl 6):S561-6. PubMed ID: 20527377
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Effects of Quercetin on Inflammation, Obesity, and Type 2 Diabetes.
Chen S; Jiang H; Wu X; Fang J
Mediators Inflamm; 2016; 2016():9340637. PubMed ID: 28003714
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the anti-inflammatory effects of safranal on high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model.
Hazman Ö; Ovalı S
Inflammation; 2015; 38(3):1012-9. PubMed ID: 25411096
[TBL] [Abstract][Full Text] [Related]
19. Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?
Maiorino MI; Bellastella G; Giugliano D; Esposito K
Endocrine; 2017 Feb; 55(2):360-365. PubMed ID: 27230767
[TBL] [Abstract][Full Text] [Related]
20. [Modulation of tissue exposure to cortisol, new perspective for reducing the metabolic risk associated with obesity].
Iovino A; Scheen AJ
Rev Med Liege; 2010 Mar; 65(3):140-6. PubMed ID: 20411818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
